Phase 4
N=60
The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients
COVID-19
Bottom Line
View on ClinicalTrials.gov: NCT04941131 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcome: Primary: E Genes — 28.50; 27.33; 30.28; 27.80 Cycle
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Chlorhexidine digluconate, povidone iodine (Drug)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- King Abdulaziz University
- Primary completion
- Jul 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY E Genes |
28.50; 27.33; 30.28; 27.80 | — |
| SECONDARY S Genes |
27.86; 26.74; 28.09; 27.87 | — |
Summary
Existing evidence confirmed that saliva and oral cavity to be a reservoir for SARS-CoV-2. In dental clinic aerosol-producing-procedures pose a significant risk for transmission of the infection . It is very important to minimize the risk of transmission in dental office reducing the load of SARS-CoV-2 in saliva if possible, in suspect or conformed cases. Preprocedural mouth rises have been used widely to minimize the number of oral microorganisms. Multiple studies confirmed the efficacy of those mouth rinses in reducing the possibility of transmission of SARS-CoV-2 infection .
Eligibility Criteria
Inclusion Criteria
- A history of positive nasal swabs for SARS-CoV-2 based on reverse-transcription polymerase chain reaction (RT-PCR) assays.
Exclusion Criteria
- History of allergy to any of the products that will be used
- known pregnancy
- Renal failure
Data sourced from ClinicalTrials.gov (NCT04941131). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.